MedTrace Logo

Specific microRNAs as Potential Biomarker for Inflammatory Bowel Disease

NCT03698500 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2018-10-09

No results posted yet for this study

Summary

The aim of this study is to assess the ability of miR-320a and other specific microRNAs to follow the disease course in patients with Crohn's disease (CD) and ulcerative colitis (UC), and to distinguish both entities, infectious colitis and healthy controls. Furthermore, the accuracy of miRNA-320a to distinguish CD or UC from irritable bowel syndrome (IBS) should be evaluated .

The study is designed as a single center non-randomised prospective trial.

Conditions

Interventions

OTHER

Removal of blood

10 ml of blood will be removed from a peripheral vene during routine diagnostical blood draw

Sponsors & Collaborators

  • University Hospital Muenster

    lead OTHER

Principal Investigators

  • Anna Friederike Cordes, MD, PhD · University Hospital Muenster, University of Muenster

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03698500 on ClinicalTrials.gov